Literature DB >> 21715507

Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.

Craig B Wilen1, Nicholas F Parrish, Jennifer M Pfaff, Julie M Decker, Elizabeth A Henning, Hillel Haim, Josiah E Petersen, Jason A Wojcechowskyj, Joseph Sodroski, Barton F Haynes, David C Montefiori, John C Tilton, George M Shaw, Beatrice H Hahn, Robert W Doms.   

Abstract

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal barriers is responsible for the vast majority of new infections. This relatively inefficient process results in the transmission of a single transmitted/founder (T/F) virus, from a diverse viral swarm in the donor, in approximately 80% of cases. Here we compared the biological activities of 24 clade B T/F envelopes (Envs) with those from 17 chronic controls to determine whether the genetic bottleneck that occurs during transmission is linked to a particular Env phenotype. To maximize the likelihood of an intact mucosal barrier in the recipients and to enhance the sensitivity of detecting phenotypic differences, only T/F Envs from individuals infected with a single T/F variant were selected. Using pseudotyping to assess Env function in single-round infectivity assays, we compared coreceptor tropism, CCR5 utilization efficiencies, primary CD4(+) T cell subset tropism, dendritic cell trans-infections, fusion kinetics, and neutralization sensitivities. T/F and chronic Envs were phenotypically equivalent in most assays; however, T/F Envs were modestly more sensitive to CD4 binding site antibodies b12 and VRC01, as well as pooled human HIV Ig. This finding was independently validated with a panel of 14 additional chronic HIV-1 Env controls. Moreover, the enhanced neutralization sensitivity was associated with more efficient binding of b12 and VRC01 to T/F Env trimers. These data suggest that there are subtle but significant structural differences between T/F and chronic clade B Envs that may have implications for HIV-1 transmission and the design of effective vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715507      PMCID: PMC3165820          DOI: 10.1128/JVI.00736-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

2.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  HIV-1 infection in a man homozygous for CCR5 delta 32.

Authors:  T R O'Brien; C Winkler; M Dean; J A Nelson; M Carrington; N L Michael; G C White
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

4.  Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1.

Authors:  M Poss; H L Martin; J K Kreiss; L Granville; B Chohan; P Nyange; K Mandaliya; J Overbaugh
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

5.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

Authors:  G J Bridger; R T Skerlj; D Thornton; S Padmanabhan; S A Martellucci; G W Henson; M J Abrams; N Yamamoto; K De Vreese; R Pauwels
Journal:  J Med Chem       Date:  1995-01-20       Impact factor: 7.446

9.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

Authors:  E De Clercq; N Yamamoto; R Pauwels; J Balzarini; M Witvrouw; K De Vreese; Z Debyser; B Rosenwirth; P Peichl; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  83 in total

1.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  A combination HIV reporter virus system for measuring post-entry event efficiency and viral outcome in primary CD4+ T cell subsets.

Authors:  Carisa A Tilton; Caroline O Tabler; Mark B Lucera; Samantha L Marek; Aiman A Haqqani; John C Tilton
Journal:  J Virol Methods       Date:  2013-09-08       Impact factor: 2.014

3.  Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.

Authors:  Laurence Meyer; Francis Barin; Mélanie Bouvin-Pley; Maxime Beretta; Alain Moreau; Emmanuelle Roch; Asma Essat; Cécile Goujard; Marie-Laure Chaix; Nathalie Moiré; Loïc Martin; Martine Braibant
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Antibody gene transfer for HIV immunoprophylaxis.

Authors:  Alejandro B Balazs; Anthony P West
Journal:  Nat Immunol       Date:  2013-01       Impact factor: 25.606

5.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

Review 6.  HIV-1 target cells in the CNS.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Christa B Sturdevant; Ronald Swanstrom
Journal:  J Neurovirol       Date:  2014-09-19       Impact factor: 2.643

7.  CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression.

Authors:  Caroline O Tabler; Mark B Lucera; Aiman A Haqqani; David J McDonald; Stephen A Migueles; Mark Connors; John C Tilton
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Macrophages sustain HIV replication in vivo independently of T cells.

Authors:  Jenna B Honeycutt; Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; John Foster; Oksana Zakharova; Stephen Wietgrefe; Carolina Caro-Vegas; Victoria Madden; Garrett Sharpe; Ashley T Haase; Joseph J Eron; J Victor Garcia
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

9.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.

Authors:  Bin Su; Alexandre Lederle; Géraldine Laumond; Camille Ducloy; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.